The effect of corticosteroid on the treatment of Kawasaki
- Conditions
- Kawasaki disease.Mucocutaneous lymph node syndrome [Kawasaki]M30.3
- Registration Number
- IRCT20181202041817N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Kawasaki disease definition according to American Heart Assosiation (AHA): Complete Kawasaki disease : Fever for more than 5 days plus at least four of the following clinical signs : Bilateral conjunctival injection, Changes in the oropharyngeal mucous membranes, including one or moreof injected and/or fissured lips, strawberry tongue, injected pharynx ,Changes in the peripheral extremities, including erythema and/or edema of the hands and feet (acute phase) or periungual desquamation (convalescent phase), Polymorphous rash, Cervical lymphadenopathy with at least one node >1.5 cm
Incomplete Kawasaki : Fever for more than 5 days plus fewer than 4 of the principal clinical findings, and compatible laboratory or echocardiographic findings.
Complicated disease( Macrophage Activating Syndrome)
Patients with frequent KD
Patients with Coronary Artery Abnormality have already been approved
Congestive Heart Failure
Chronic renal failure
Sensitization to Methyl Prednisolone or Prednisolone
Active viral viral zoster infection; or exposure to Varicella in the past 21 days if not safe
Injection of Oral, Intravenous or Muscular Corticosteroids> 3 days in the last 7 days
History of severe reaction to the preparation of any human globulin product
Registering in another study that may affect the effects of treatment, effectiveness, or follow-up.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Coronary Artery abnormality in the Kawasaki disease. Timepoint: Echocardiography is performed at least three times (immediately at the beginning of the diagnosis, two weeks and two months after the onset of the disease). Method of measurement: Echocardiography.;Reduction of Coronary Artery abnormality in the Kawasaki disease. Timepoint: Echocardiography is performed at least three times (immediately at the beginning of the diagnosis, two weeks and two months after the onset of the disease). Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method The severity of coronary artery disease. Timepoint: At least three times (immediately at the start of the diagnosis, two weeks and two months after the onset of the disease). Method of measurement: Echocardiography.;Prevalence of coronary artery involvement. Timepoint: before intervention, 14 and 60 days after onset of treatment. Method of measurement: echocardiography.